Travel Medicine and Infectious Disease
Volume 8, Issue 1 , Pages 47-50, January 2010

Quadrivalent meningococcal vaccines: Hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine

Novartis Vaccines and Diagnostics GmbH, Global Medical Affairs, Emil-von-Behring-Straße 76, 35041 Marburg, Germany

Received 23 July 2009; received in revised form 7 December 2009; accepted 9 December 2009. published online 11 January 2010.

Summary 

Regional variations in the incidence and the distribution of serogroups which are responsible of meningococcal disease necessitate multivalent vaccines to ensure broad coverage for travelers. For almost 30years, this has been provided by quadrivalent polysaccharide vaccine to protect against serogroups A, C, W-135 and Y, but with the advent of quadrivalent conjugate vaccines is there still a case to use the polysaccharide? The well documented hyporesponsiveness induced by polysaccharide vaccines after repeated administration, most clearly observed against serogroup C, suggest that, where available, conjugate vaccines should always be considered ahead of polysaccharide vaccine.

Keywords: Meningococcal vaccines, Hyporesponsiveness, Conjugate vaccine, Polysaccharide vaccine

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 12.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1477-8939(09)00179-3

doi:10.1016/j.tmaid.2009.12.001

Travel Medicine and Infectious Disease
Volume 8, Issue 1 , Pages 47-50, January 2010